The current structure of global incentives to develop new antibiotics is insufficient and requires urgent resolution revealed a new report 'Incentivising new
antibiotics' by the Office of Health Economics (OHE).
OHE analysis demonstrates that on a global level, it is estimated that an effective 10-year incentive would require £3.5bn ($4.2bn) to adequately cover the entire
research and development process for a new antibiotic.
The report considers how health systems in the UK and around the world can stimulate the research and development (R&D) of new antibiotics.
In 2020, the National Institute for Health and Care Excellence (NICE) and NHS England initiated an Antimicrobial Resistance pilot with the aim of incentivising
pharmaceutical companies to develop new antibiotics by addressing the issues associated with reimbursement, which historically has deterred companies from pursuing
AMR research.
The drug, 'durvalumab', can double the overall time someone can survive with an aggressive form of lung cancer from two-and-a-half to five years.
It has been approved by the National Institute for Health and Care Excellence (NICE) and the NHS has sealed a deal with manufacturer AstraZeneca to begin rolling
it out.
The new treatment will be offered to more than 550 patients a year with advanced non-small-cell lung cancer (NSCLC) who have already undergone both chemotherapy
and radiotherapy concurrently.
NHS said: "The drug can stop the cancer from getting worse for more than two years - significantly longer than treatment with a combination of chemotherapy and
radiotherapy, which can only hold the disease at bay for around six months. This increases overall survival time and gives patients more precious moments with their
loved ones."
Dame Cally Palmer, national cancer director for NHS England, said: "We are resolute in our ambition to fight the devastating effects of cancer and new pioneering
treatments like durvalumab are a vital lifeline for people living with cancer - giving them more precious time with family and friends.